Dr. Lorenzo Gianni - Oncologia Rimini

More documents

Recommendations

Info

Sorafenib: studio IIb randomizzato, doppio cieco: HER2-, 1° linea Gradishar WJ,et al. SABCS 2009. #44 SABCS09_GS4_04
Risultati PFS (endpoint 1°) mesi S + wP Pl + wP HR; 95%CI 6,9 5,6 0.788; 0.6-1.1 TTP mesi 8.1 5.6 0.674; 0.5-0.9 p 0.0857 0.0171 ORR % 67 54 0.0234 mDOR mesi 5.6 3.7 0.0079 Decessi (Onstudy) • PD • TR*-AE • TU**-AE 16 (14%) 7 (6%) 2(2%) 7 (6%) 4 (3%) 2 (2%) 0 (0%) 2 (2%) */**TR/U: treatment related/unrelated Gradishar WJ,et al. SABCS 2009. #44 SABCS09_GS4_04
Page 1 and 2: Caratteristiche biologiche e ruolo
Page 3 and 4: VEGF e recettori VEGF-R • Famigli
Page 5 and 6: Espressione VEGF nella malattia pre
Page 8 and 9: Angiogenesis and lymphangiogenesis
Page 10 and 11: Transduzione del segnale e processi
Page 12 and 13: Effetto inibitori angiogenesi e pos
Page 14 and 15: Metronomic vs conventional scheduli
Page 16 and 17: Rapid Chemotherapy-Induced Acute En
Page 18 and 19: AVF2119g trial CAP 2500 mg CAP + BV
Page 20 and 21: RIBBON-II Brufsky A, Bondarenko IN,
Page 22 and 23: Brufsky A, Bondarenko IN, et al. SA
Page 24 and 25: MO19391 (ATHENA trial) Pierga J, et
Page 26 and 27: MO19391: ATHENA trial 100 Complete
Page 28 and 29: MO19391: ATHENA trial. Elderly vs n
Page 30 and 31: Endpoints di efficacia selezionati:
Page 32 and 33: AVADO trial: disegno, arruolamento
Page 34 and 35: RIBBON-1: PFS Robert N, et al. ASCO
Page 36 and 37: RIBBON-1: ORR e OS Robert N, et al.
Page 38 and 39: N0432:phase II trial of docetaxel w
Page 40 and 41: SABRE: Sunitinib + wP-BV: significa
Page 42 and 43: Bevacizumab + Letrozole PR as best
Page 44 and 45: SUN 1064 study Bergh J. ASCO 2010:
Page 46 and 47: Sunitinib vs Capecitabina nell’AB
Page 48 and 49: CIRG/TORI 010: risultati (ITT) wP+P
Page 52 and 53: SOLTI-0701: studio IIb randomizzato
Page 54 and 55: Baselga J, et al. SABCS 2009. #45 S
Page 56 and 57: Sicurezza BV in pz con metastasi SN
Page 58 and 59: Complicanze chirurgiche BV in neoad
Page 60 and 61: Complicazioni chirurgiche: non sign
Page 62 and 63: Quali ragioni per beneficio < alle
Page 64: Terapie antiangiogenetiche nel ca m

Dr. Lorenzo Gianni - Oncologia Rimini

Create successful ePaper yourself

Delete template?

Save as template?